PILA PHARMA is a privately held clinical stage pharmaceutical company based in Malmö, Sweden.
PILA PHARMA is developing a novel type of oral anti-diabetic agent: a TRPV1 antagonist for the treatment of diabetes.
XEN-D0501, the recently purchased, safe clinical development candidate, will enter the first clinical trials in type-2 diabetic patients in 2017.
PILA PHARMA yesterday won the title “Årets pitchare 2016” at the ALMI Invest Seed Day in Stockholm, Sweden!
The 1-min pitch competition was held amongst 17 selected out of ALMI Invests 400 portfolio companies.